The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID)

Hypertension Research

Volumn 36, Issue 2, 2013, Pages 140-150

  Yamazaki, Tsutomu ^a   Kohro, Takahide ^b   Chujo, Mitsuaki ^c   Ishigaki, Masahide ^c   Hashimoto, Takafumi ^c  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

cardiac events; cerebrovascular events; post marketing surveillance; valsartan

Indexed keywords

VALSARTAN;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BENIGN TUMOR; BRAIN HEMORRHAGE; BRAIN INFARCTION; BREAST DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASES; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENETIC DISORDER; HEADACHE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION; INJURY; INNER EAR DISEASE; INTOXICATION; JAPAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MUSCLE ISCHEMIA; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PULSE RATE; RISK REDUCTION; SKIN DISEASE; SUBARACHNOID HEMORRHAGE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

AGED; ANGINA PECTORIS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CEREBROVASCULAR DISORDERS; FEMALE; HEALTH SURVEYS; HEART FAILURE; HUMANS; HYPERTENSION; INCIDENCE; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84873536849     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.154     Document Type: Article

References (42)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC-7 Report. JAMA 2003; 289: 2560-2572.
2. Veterans Administration cooperative study group on antihypertensive agents. Effects of treatment on morbidity in hypertension; results in patients with diastolic blood pressures averaging 115 through 129mmHg. JAMA 1967; 202: 1028-1034.
3. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997; 350: 757-764.
4. Dahlö f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
5. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension Guidelines for the Management of Hypertension 2009. Life Science Publishing, Tokyo, 2009.
6. Summary of Vital Statistics: trends in leading causes of death, Vital Statistics, Ministry of Health, Labour and Welfare, Japan, 2010. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/suii02/deth7.html. Accessed on April 27 2012.
7. Mori H, Ukai H, Yamamoto H, Saitou S, Hirao K, Yamauchi M, Umemura S. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-151.
8. Kannel WB. Histolic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138(3 part 2): 205-210.
9. Cristione L, Gasparo M, Buhlmayer P, Whitebread S, Ramojoune H, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110: 761-771.
10. The Japanese Circulation Society. Guidelines for the management of patients with STelevation myocardial infarction (JCS 2008). http://www.j-circ. or.jp/guideline/pdf/JCS2008-takano-h.pdf. Accessed on April 27 2012.
11. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
12. The Japanese Circulation Society. Guidelines for Treatment of Acute Heart Failure (JCS 2011). http://www.j-circ.or.jp/guideline/pdf/JCS2011-izumi-h.pdf. Accessed on April 27 2012.
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446.
14. Kim J, Jacobs Jr DR, Luepker RV, Shahar E, Margolis KL, Becker MP. Prognostic value of a novel classification scheme for heart failure: the Minnesota Heart Failure Criteria. Am J Epidemiol 2006; 164: 184-193.
15. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Guidelines for the Management of Hypertension 2000 (JSH 2000). Japanese Society of Hypertension, Tokyo, 2000.
16. The GLANT study group. A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension; the GLANT study. Hypertens Res 1995; 18: 235-244.
17. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-1839.
18. Kadota A, Hozawa A, Okamura T, Kadowak T, Nakmaura K, Murakami Y, Hayakawa T, Kita Y, Okayama A, Nakamura Y, Kashiwagi A, Ueshima H; NIPPON DATA Research Group. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care 2007; 30: 1533-1538.
19. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama study. Diabetes 1996; 45(Suppl 3): S14-S16.
20. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68: 228-236.
21. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-1076.
22. Blood Pressure Lowering Treatment Trialists' Collaboration; Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951-958.
23. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003; 34: 2741-2748.
24. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21: 707-716.
25. Okayama A, Kadowaki T, Okamura T, Hayakawa T, Ueshima H; The NIPPON DATA80 Research Group. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). J Hypertens 2006; 24: 459-462.
26. Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010; 28: 1356-1365.
27. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73913 patients. J Hypertens 2011; 29: 1253-1269.
28. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigatorsPrognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens 2009; 27: 1360-1369.
29. Hansson L, Zanchetti A, Carruthers SG, Dahlö f B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet 1998; 351: 1755-1762.
30. Rosendorff C, Black HR. Evidence for a lower target blood pressure for people with heart disease. Curr Opin Cardiol 2009; 24: 318-324.
31. Lim MA, Townsend RR. Arterial compliance in the elderly: its effect on blood pressure measurement and cardiovascular outcomes. Clin Geriatr Med 2009; 25: 191-205.
32. Satish S, Zhang DD, Goodwin JS. Clinical significance of falling blood pressure among older adults. J Clin Epidemiol 2001; 54: 961-967.
33. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a metaanalysis of individual-patient data. Ann Intern Med 2002; 136: 438-448.
34. Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press 2009; 18: 168-170.
35. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G; Cardio-Sis investigatorsUsual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet 2009; 374: 525-533.
36. Shimamoto K, Fujita T, Ito S, Naritomi H, Ogihara T, Shimada K, Tanaka H, Yoshiike N; J-HEALTH Study Committees. Impact of blood pressure control on cardiovascular events in 26512 Japanese hypertensive patients: the Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH) study, a prospective nationwide observational study. Hypertens Res 2008; 31: 469-478.
37. Ogihara T, Matsuoka H, Rakugi H. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int 2011; 11: 414-421.
38. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
39. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedelijković S, Nissinen A, Toshima H. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the seven countries study. JAMA 1995; 274: 131-136.
40. Saito I, Folsom AR, Aono H, Ozawa H, Ikebe T, Yamashita T. Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 2000; 29: 837-844.
41. Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54: 1827-1834.
42. Grossman E. Blood pressure: the lower, the better: the con side. Diabetes Care 2011; 34(Suppl 2): S308-S312.